lonafarnib has been researched along with Hepatitis B in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, AU; Lee, C | 1 |
| Caviglia, GP; Ibadullaeva, N; Ismoilov, U; Joldasova, E; Khikmatullaeva, A; Khodjaeva, M; Musabaev, E; Rizzetto, M; Said, S; Shahnoza, A | 1 |
| Elazar, M; Glenn, JS | 1 |
2 review(s) available for lonafarnib and Hepatitis B
| Article | Year |
|---|---|
Hepatitis D Review: Challenges for the Resource-Poor Setting.
Topics: Antiviral Agents; Drug Therapy, Combination; Europe; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis D; Humans; Interferon-alpha; Lipopeptides; Piperidines; Pyridines; Treatment Outcome; Viral Load; Virus Replication | 2021 |
Emerging concepts for the treatment of hepatitis delta.
Topics: Animals; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis D; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Liver Cirrhosis; Liver Neoplasms; Mice; Piperidines; Pyridines | 2017 |
1 other study(ies) available for lonafarnib and Hepatitis B
| Article | Year |
|---|---|
Hepatitis D virus in Uzbekistan.
Topics: Adult; Chronic Disease; Female; Fibrosis; Global Burden of Disease; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis D; Hepatitis Delta Virus; Humans; Incidence; Interferon-alpha; Lipopeptides; Liver Diseases; Male; Middle Aged; Piperidines; Prevalence; Pyridines; Risk Factors; Superinfection; Uzbekistan | 2020 |